NEKTAR THERAPEUTICS — fact timeline

NEKTAR THERAPEUTICS shareholders approved Approve non-binding advisory resolution regarding executive compensation at the 2026-06-04 meeting.

“The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”

NEKTAR THERAPEUTICS shareholders approved Ratify selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with the following votes.”

NEKTAR THERAPEUTICS shareholders approved Approve amendment to the Amended and Restated 2017 Performance Incentive Plan to increase authorized shares by 3,000,000 shares at the 2026-06-04 meeting.

“The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares was approved with the following votes.”

NEKTAR THERAPEUTICS shareholders approved Election of Director Howard W. Robin at the 2026-06-04 meeting.

“The individual listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the “Board”) until the Company’s 2029 Annual Meeting of Stockholders.”

NEKTAR THERAPEUTICS entered into Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC valued at $150,000,000 (effective 2026-05-08).

“On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.”

Linda Rubinstein was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.

“Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.”

Sandra Gardiner departed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.

“On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.”

NEKTAR THERAPEUTICS reported first quarter ended March 31, 2026 results: revenue 10.9 million, net income 44.9 million, EPS 1.82.

“Revenue in the first quarter of 2026 was $10.9 million as compared to $10.5 million in the first quarter of 2025.”

NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately $350.9 million (effective 2026-04-21).

“On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,532,609 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”) at a price to the public of $92.00 per Firm Share, less underwriting discounts and commissions.”

NEKTAR THERAPEUTICS reported full year 2025 results: revenue $55.2 million, net income $164.1 million, EPS $9.73 basic and diluted loss per share.

“Revenue for the full year of 2025 was $55.2 million compared to $98.4 million in 2024.”

NEKTAR THERAPEUTICS reported the fourth quarter ended December 31, 2025 results: revenue $21.8 million, net income $36.1 million, EPS $1.78 basic and diluted net loss per share.

“Revenue in the fourth quarter of 2025 was $21.8 million as compared to $29.2 million in the fourth quarter of 2024.”

NEKTAR THERAPEUTICS entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. valued at approximately 432.0 million (effective 2026-02-11).

“On February 11, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”)”

NEKTAR THERAPEUTICS: Effected one-for-fifteen reverse stock split effective June 8, 2025 (effective 2025-06-08).

“On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Reverse Stock Split Amendment”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s Common Stock at a ratio of one-for-fifteen (the “Reverse Stock Split”).”

NEKTAR THERAPEUTICS: Increased authorized common shares from 300M to 390M (effective 2025-06-06).

“On June 6, 2025, Nektar Therapeutics (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Increase in Authorized Shares Amendment”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), from 300,000,000 shares to 390,000,000 shares.”

NEKTAR THERAPEUTICS reported first quarter ended March 31, 2024 results: revenue $21.6 million, net income $36.8 million or $0.19 basic and diluted loss per share, EPS $0.19 basic and diluted loss per share.

“the TNFR2 receptor is progressing through IND-enabling studies to support entering the clinic next year.” Summary of Financial Results Revenue in the first quarter of 2024 was $21.6 million as compared to the same $21.6 million in the first quarter of 2023. Total operating costs and expenses in the first quarter of 2024 were $57.1 million as compared to $156.3”

NEKTAR THERAPEUTICS reported the year ended December 31, 2023 results: revenue $90.1 million, net income $276.1 million or $1.45 basic and diluted loss per share.

“Revenue for the year ended December 31, 2023 was $90.1 million as compared to $92.1 million in 2022.”

NEKTAR THERAPEUTICS reported the fourth quarter and year ended December 31, 2023 results: revenue $23.9 million, net income $42.1 million or $0.22 basic and diluted loss per share.

“we are also conducting IND-enabling studies for NKTR-0165, our novel agonist antibody targeting TNFR2.” Summary of Financial Results Revenue in the fourth quarter of 2023 was $23.9 million as compared to $22.0 million in the fourth quarter of 2022. Revenue for the year ended December 31, 2023 was $90.1 million as compared to $92.1 million in 2022. Total operating”

NEKTAR THERAPEUTICS amended Amendment No 1 to Purchase and Sale Agreement with Healthcare Royalty valued at $15 million cash payment (effective 2024-03-04).

“On March 4, 2024, Nektar Therapeutics (“Nektar”) and entities managed by Healthcare Royalty entered into an Amendment No 1. (the “Amendment”) to that certain Purchase and Sale Agreement, dated as of December 16, 2020, as more fully described in Nektar’s Current Report on Form 8-K filed on December 22, 2020 (the “Purchase Agreement”).”

NEKTAR THERAPEUTICS entered into Purchase Agreement with TCG Crossover Fund II, L.P. valued at $30.0 million (effective 2024-03-04).

“On March 4, 2024, Nektar Therapeutics (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with TCG Crossover Fund II, L.P. (the “Purchaser”), for the private placement (the “Private Placement”) of a pre-funded warrant (the “Pre-Funded Warrant”) to purchase 25,000,000 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (the “Warrant Shares” and together with the Pre-Funded Warrant, the “Securities”), at a total purchase price of $30.0 million”

NEKTAR THERAPEUTICS terminated share purchase agreement with Bristol-Myers Squibb Company (effective 2024-02-12).

“Nektar entered into a privately negotiated Stock Repurchase Agreement with BMS pursuant to which, among other things, Nektar purchased from BMS all of the BMS Nektar Shares (the “Stock Repurchase”) for an aggregate purchase price of $3,000,000 and all rights and obligations of the parties under the Purchase Agreement and the IA were terminated.”

NEKTAR THERAPEUTICS received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“November 24, 2023, the Company received a written notice (the “Notice”) from Nasdaq stating that the Company is eligible for an additional 180 calendar day period, or until May 20, 2024, to regain compliance with the minimum bid price requirement. In the Notice, Nasdaq noted that the Company’s common stock had not regained compliance with the minimum bid price requirement during the initial 180 calendar day period that ended on November 22, 2023, and that the Company had submitted written notice to Nasdaq of its intention to cure the required minimum bid price deficiency by effecting a reverse”

NEKTAR THERAPEUTICS reported the third quarter ended September 30, 2023 results: revenue $24.1 million, net income Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share, EPS $0.24 basic and diluted loss per share.

“least $320 million in cash and investments which provides us with a cash runway into the middle of 2026.” Summary of Financial Results Revenue in the third quarter of 2023 was $24.1 million as compared to $23.6 million in the third quarter of 2022. Revenue for the first nine months of 2023 was $66.2 million as compared to $70.0 million in the first nine months of”

NEKTAR THERAPEUTICS terminated Strategic Collaboration Agreement with Bristol-Myers Squibb Company (effective 2023-09-06).

“the parties entered into a letter agreement (the “Letter Agreement”) to terminate the Strategic Collaboration Agreement.”

NEKTAR THERAPEUTICS reported the second quarter ended June 30, 2023 results: revenue $20.5 million, net income $51.1 million or $0.27 basic and diluted loss per share, EPS $0.27 basic and diluted loss per share.

“our Phase 2 studies of NKTR-255 in liquid and solid tumors as we evaluate strategic partnership pathways.” Summary of Financial Results Revenue in the second quarter of 2023 was $20.5 million as compared to $21.6 million in the second quarter of 2022. Revenue for the first half of 2023 was $42.1 million as compared to $46.4 million in the first half of 2022. Total”

Jillian Thomsen departed as Chief Financial Officer at NEKTAR THERAPEUTICS.

“On April 17, 2023, Nektar Therapeutics (the “Company”) announced that Jillian Thomsen will step down as the Chief Financial Officer of the Company effective as of April 17, 2023”

NEKTAR THERAPEUTICS shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-06-08 meeting.

“Proposal 5 The proposal to vote on the frequency with which the Company’s stockholders will be provided a vote, on a non-binding advisory basis, on the compensation of the Company’s Named Executive Officers, received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 131,842,535 91,293 2,367,608 336,176 21,642,427”

NEKTAR THERAPEUTICS shareholders approved Advisory vote to approve compensation of Named Executive Officers at the 2023-06-08 meeting.

“Proposal 4 The proposal to approve the compensation of the Company’s Named Executive Officers, on a non-binding advisory basis, was approved with the following votes. For Against Abstain Broker Non-Votes 114,458,620 19,391,723 787,269 21,642,427”

NEKTAR THERAPEUTICS shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.

“Proposal 3 The proposal to ratify the appointment, by the audit committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved with the following votes. For Against Abstain Broker Non-Votes 152,198,308 3,794,659 287,072 0”

NEKTAR THERAPEUTICS shareholders approved Approval of amendment to Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 12,000,000 shares at the 2023-06-08 meeting.

“Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 12,000,000 shares was approved with the following votes. For Against Abstain Broker Non-Votes 128,177,858 6,147,762 311,992 21,642,427”

NEKTAR THERAPEUTICS shareholders approved Election of Directors at the 2023-06-08 meeting.

“Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the “Board”) until the Company’s 2026 Annual Meeting of Stockholders. Nominee For Against Abstain Broker Non-Votes Myriam J. Curet 86,013,697 48,360,669 263,246 21,642,427 Howard W. Robin 131,440,338 2,940,207 257,067 21,642,427”

NEKTAR THERAPEUTICS received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“May 26, 2023, Nektar Therapeutics (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Global Select Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”) because the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Com”

NEKTAR THERAPEUTICS reported first quarter ended March 31, 2023 results: revenue $21.6 million, net income $137.0 million, EPS $0.73 basic and diluted loss per share.

“to advance our immunology research pipeline with the goal of advancing a new IND candidate next year.” Summary of Financial Results Revenue in the first quarter of 2023 was $21.6 million as compared to $24.8 million in the first quarter of 2022. Total operating costs and expenses in the first quarter of 2023 were $156.3 million as compared to $141.4 million in”

NEKTAR THERAPEUTICS terminated License Agreement with Eli Lilly and Company valued at termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald (effective 2023-07-22).

“greement (the “Agreement”) with Eli Lilly and Company (“Lilly”), which Agreement was filed as an exhibit to Nektar’s Quarterly Report on Form 10-Q for the period ended September 30, 2017.”

NEKTAR THERAPEUTICS announced a restructuring with charges of non-recurring cash payments of approximately $8 million affecting San Francisco-based workforce (approximately 60%).

“On April 17, 2023, the duly authorized officers of the “Company approved a new strategic reprioritization and cost restructuring plan (the “2023 Restructuring Plan”). Pursuant to the 2023 Restructuring Plan, the Company will undertake several cost-reduction actions to reduce costs, including a reduction in its San Francisco-based workforce by approximately 60% that is expected to be substantially completed by June 2023. In connection with these actions, the Company expects non-recurring cash payments of approximately $8 million primarily in the second quarter of 2023 associated principally with the workforce reduction, including one-time employee severance and termination payments.”

Sandra Gardiner was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.

“Effective April 17, 2023, Sandra Gardiner, a partner in FLG Partners, LLC, a Silicon Valley chief financial officer services and board advisory firm (“FLG”), will be retained as the interim Chief Financial Officer and shall be the principal financial and accounting officer of the Company.”

Jillian Thomsen departed as Chief Financial Officer at NEKTAR THERAPEUTICS.

“On April 17, 2023, Jillian Thomsen stepped down as the Chief Financial Officer of the Company and will depart the Company in June 2023 following a transition period.”

Karin Eastham departed as Director at NEKTAR THERAPEUTICS.

“On April 6, 2023, Karin Eastham informed the Board of Directors (the “Board”) of Nektar Therapeutics (the “Company”) that she has elected not to stand for re-election and will complete her term on the Board at the conclusion of the Company’s 2023 annual meeting of stockholders.”

NEKTAR THERAPEUTICS reported the quarter and year ended December 31, 2022 results: revenue Revenue in the fourth quarter of 2022 was $22.0 million, net income Net loss for the fourth quarter of 2022 was $59.7 million, EPS $0.32 basic and diluted loss per share.

“On February 28, 2023, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2022.”

NEKTAR THERAPEUTICS: Amended the Amended and Restated Bylaws to reflect changes in DGCL, adopt universal proxy rules, and enhance stockholder proposal requirements (effective 2022-12-15).

“On December 15, 2022, in connection with the new Securities and Exchange Commission rules and changes to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of corporate governance matters, the Board of Directors (the “Board”) of Nektar Therapeutics (the “Company”), approved amendments to the Company’s Amended and Restated Bylaws (the “Bylaws”), effective immediately.”

NEKTAR THERAPEUTICS reported third quarter ended September 30, 2022 results: revenue $23.6 million, net income $59.0 million, EPS $0.31 basic and diluted loss per share.

“lay the foundation for continued pipeline progress.” Summary of Financial Results Revenue, which primarily includes non-cash royalty revenue, in the third quarter of 2022 was $23.6 million as compared to $24.9 million in the third quarter of 2021. Revenue for the first nine months of 2022 was $70.0 million as compared to $76.9 million in the first nine months of”

John Northcott departed as Senior Vice President and Chief Commercial Officer at NEKTAR THERAPEUTICS.

“On April 25, 2022 (the “Notice Date”), the Company announced that John Northcott will step down from the role of Senior Vice President and Chief Commercial Officer of the Company.”

Jillian Thomsen changed role as Senior Vice President and Chief Financial Officer at NEKTAR THERAPEUTICS.

“On July 1, 2022, the Company announced the promotion of Jillian Thomsen, who currently serves as Senior Vice President, Finance and Chief Accounting Officer, to the position of Senior Vice President and Chief Financial Officer, effective as of July 1, 2022.”

Gil Labrucherie departed as Chief Financial Officer and Chief Operating Officer at NEKTAR THERAPEUTICS.

“On July 1, 2022, Nektar Therapeutics (the “Company”) announced that Gil Labrucherie will step down as Chief Financial Officer and Chief Operating Officer of the Company, effective as of July 1, 2022.”

John Northcott departed as Senior Vice President and Chief Commercial Officer at NEKTAR THERAPEUTICS.

“John Northcott will step down as Senior Vice President and Chief Commercial Officer of the Company in June 2022.”

Diana M. Brainard, M.D. was appointed as Class III Director at NEKTAR THERAPEUTICS.

“On November 11, 2021, Diana M. Brainard, M.D. was appointed to the board of directors (the “ Board ”) of Nektar Therapeutics, a Delaware corporation (the “ Company ”), as a Class III Director”